Objective: In United Kingdom., test of cure after treatment of any grade of cervical intraepithelial neoplasia (CIN) incorporates high-risk human papillomavirus (Hr-HPV) test and cytology at 6-month follow-up. The aims of the study were to determine the rate of recurrent CIN in women who are Hr-HPV positive and cytology negative and to explore possible associated risk factors.
I
n the United Kingdom, cervical cancer is the second most common cancer in women younger than 35 years. 1 Prevention of the mainly, as yet, unvaccinated target population centers on cervical screening and the detection and treatment of cervical intraepithelial neoplasia (CIN) in the screen-positive population. However, women treated for CIN remain at 5-fold risk of cervical cancer up to 20 years after treatment. 2 Human papillomavirus (HPV) infection is necessary for the development of CIN and cervical cancer. 3 The high sensitivity and negative predictive value of high-risk HPV (Hr-HPV) testing have been exploited to improve posttreatment surveillances. 4 Therefore, individuals with Hr-HPV negative test and negative cytology can safely return to 3 yearly routine recall management screenings, 5 and women who test positive undergo further evaluation.
In Scotland, posttreatment surveillance is a standard practice in the National Health Service (NHS), known as "test of cure" (ToC). 5, 6 The ToC of any grade-treated CIN incorporates Hr-HPV test and cytology at 6 months' follow-up in primary care. 5 The ToC was first introduced in our region in 2010 as an early implementation site in Scotland. In Scotland, women who fail ToC continue to have annual cytology for 5 years even if colposcopy is normal. In Scotland, the colposcopy quality assurance standard after treatment of CIN is to achieve 90% of women with negative cytology 6 months after treatment and the rate of histologically confirmed residual CIN of less than 5% at 12 months.
We would anticipate that with cytology-negative women but Hr-HPV positive, we would increase the proportion of residual or recurrent CIN detected within 12 months of treatment. This should reduce the number of cases detected later. Therefore, we aimed to determine the incidence of recurrent CIN in women Hr-HPV positive/cytology negative after treatment for CIN and to explore possible associated risk factors.
Materials and Methods
Our clinic in Aberdeen Royal Infirmary serves a geographically defined population with a single pathology and cytology laboratory. Women were referred through the Scottish Cervical Screening Programme, and we performed 450 treatments for CIN per year approximately. All HPV tests were performed at the National HPV Reference Laboratory in Edinburgh using the Abbott RealTime High-Risk HPV assay (Abbott Molecular, IL). Colposcopy data were collected routinely for all referred individuals in NHS Scotland via the National Colposcopy Clinical Information and Audit System. This database is episode based and includes patient demographics, appointment details, clinical data (referral, clinical signs, and symptoms), colposcopy assessment and findings, histology and cytology results, treatments, and the follow-up management plan.
We performed a retrospective observational cohort study of women treated for any grade CIN, as per national guidelines by accredited colposcopists and trainees of British Society Cervical Cancer and Pathology, who had failed ToC (Hr-HPV positive but with negative cytology) between 2010 and 2015. Women with a final diagnosis at the time of initial treatment of invasive carcinomas and cervical glandular intraepithelial neoplasia were excluded. Follow-up data on cytology, colposcopy, and histology were collected up to December 2016. Follow-up was measured until December 31, 2016, unless a woman was identified with CIN recurrence when further follow-up was censored from that date. Permission to collect clinical data was given by NHS Grampian Clinical Effectiveness Department (clinical audit reference number 3691).
Patients were classified based on age at surgery into groups: 25 years or younger, 26 to 45 years, and 46 or older years. Various studies have documented significant predictive determinants that help identify individuals at high risk of CIN recurrence or persistence. 3, [7] [8] [9] Thus, based on the literature, we examined potential risk factors of posttreatment CIN recurrence and/or Hr-HPV persistence. The most common includes age, parity, smoking status, HPV vaccination status, referral cytology, definitive histology at treatment, and excision margins status.
Data Analysis
Quantitative variables are presented as mean and ranges. 
RESULTS
During the study period, a total of 2729 women were treated for any grade CIN in Aberdeen Royal Infirmary. Two hundred three women (7.8%) had negative smears but Hr-HPV positive test at ToC and formed our study group. The mean age of our study group was 31.56 years (range = 19-62 years). The mean time of follow-up per woman was 30.50 months (range = 2-63 months). Demographic characteristics of the study cohort and the women with recurrent CIN are presented in Table 1 .
The colposcopic impression after failed ToC is presented in Table 2 . Of the 42 women with a biopsy, 20 (83.3%) had CIN 1, 3 (12.5%) had CIN 2, and 1 (4.2%) had CIN 3. The management plan after colposcopy is given in Table 2 , with 155 women (72.8%) advised to have an annual colposcopic assessment.
The incidence of any grade of CIN was 11.3% and 1.9% CIN 2/3 at 6 months after treatment. Five women (2.3%) had biopsyproven CIN 2/3 within 12 months after treatment. Women treated for high-grade CIN had a negative cytology rate at 91.5% 6 months after treatment and histologically confirmed CIN at 3.8% 12 months after treatment. The survival curve analysis of women with normal and adequate colposcopy (n = 196) is presented in Figure 1 . Finally, a total of 11 women (5.2%) had repeat treatment, and final pathology diagnosis at second large loop excision of the transformation zone (LLETZ) was 1 CIN 1 (9.0%), 5 CIN 2 (45.5%), 5 CIN 3 (45.5%). Six women (2.8%) had persistent CIN 1 during their follow-up visits and were managed conservatively. One woman (0.5%) had been diagnosed with There was no statistically significant difference between age, parity, smoking status, referral cytology, definitive histology at LLETZ, and excision margins status between women with CIN recurrence/persistence and women with no CIN who were Hr-HPV positive/cytology negative (see Table 3 ).
DISCUSSION
In this retrospective observational cohort study, we have measured the outcome of women who were HPV positive/cytology negative on the ToC pathway. We also assessed possible risk factors of residual or recurrent CIN in women who fail ToC with Hr-HPV positive/negative cytology in Northeast of Scotland. To our knowledge, this is one of the few population-based studies investigating the previously mentioned factors.
Development of cervical cancer is an ongoing multifactorial process through a well-defined precursor phase where interpretation, diagnosis, and treatment in preinvasive phase is crucial. 5, 10 Surgical treatment by LLETZ or loop electrical excision procedure is the "criterion standard" technique for treating CIN. 7 Large loop excision of the transformation zone/loop electrical excision procedure has a high curative rate, but women treated for CIN are susceptible to recurrence within 2 years after treatment. 7, 11 Thus, it is recommended that women treated for CIN should be kept under posttreatment follow-up.
Different methods have been evaluated for posttreatment follow-up including cervical cytology, HPV DNA genotyping, and colposcopy. 12, 13 Each method varies in methodology, as well as in length/frequency of follow-up. 5 Combined cytology and HPV testing has been implemented by many screening programs, although the assays used and timing may vary. 5 Evaluation of the specificity and sensitivity of HPV testing and cytology demonstrated pooled sensitivity and specificity of 93% (95% CI = 85%-97%) and 81% (95% CI = 74%-86%) for HPV testing versus 72% (95% CI = 66%-78%) and 84% (95% CI = 80%-87%) for the cytology, respectively.
14 Therefore, individuals with Hr-HPV-negative test and negative cytology can safely return to routine recall management screening protocol. 5 Good practice in colposcopy comprises the distinction of normal from the abnormal transformation zone. 15 A normal examination is vital to minimize the risk of undetected disease and development of cancer and is essential to sustain confidence and compliance within a quality assured cervical screening program. 15 In our study group, we found that the incidence of any grade of CIN was 11.3% 6 months after treatment. Only 5 women (2.3%) had biopsy-proven CIN 2/3 within 12 months after treatment. The overall cure rate of CIN from our unit meets the quality performance indicator. 16 It is also important to mention that in our group, no cases of CIN 3+ were detected after negative colposcopy during the follow-up period. Concerns have been raised about the performance and accuracy of colposcopy. 17 However, 2 large studies from the United Kingdom, in the context of women referred with low-grade cytology, both found very low rates of CIN 3+ by the next round of screening. 15, 18 A normal colposcopic examination can reassure women that even with a positive HPV test, the risk of developing CIN 2 or worse is sufficiently low to return to the routine recall. 15, 18 Thus, our results with annual cytology for 5 years also confirm the importance of normal colposcopy in a different colposcopy population. Moreover, our results support the practice where women who are Hr-HPV positive and cytology negative after treatment of CIN with normal adequate colposcopy are discharged to routine recall 16 in the context of a quality assured screening program and colposcopy.
The Abbott RealTime Hr-HPV assay, which is used for ToC in Scotland, 19 is an DNA-based assay that provides results of positivity for Hr-HPV if one of the following types is present: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. 19 It also provides concurrent genotyping of 16 and 18, 19 but these data are not provided to smear taker. Thus, we cannot comment on limited genotyping and the importance of type-specific persistent HPV infections.
Human papillomavirus vaccination should reduce the risk of cervical cancer by at least 70%. 20 The UK HPV immunization program started in 2008, and uptake in Scotland has been high (>91%). 20 Vaccinated women attending for cervical screening have a significant lower Hr-HPV infection incidence. 19 In our study group, the vaccination uptake was very low, because only 5 women (2.3%) have been fully vaccinated, which supports the previously mentioned evidence.
In other countries, it is now a common practice to follow-up patients 6 to 12 months after treatment 5, 21, 22 ; in Ireland, HPV DNA test is performed at 6 months in colposcopy clinic and then 12 months in primary care, 21 whereas in Sweden, HPV DNA test and cytology are done 6 months after treatment. 22 Most women in our group diagnosed with CIN 6 months after treatment were found to regress to normal within 12 months. Therefore, whether ToC is performed prematurely at 6 months after treatment needs to be further evaluated because most women would clear from HPV in 12 months. In that way, false-positive results, which may be seen in United Kingdom when we test at 6 months, may reduce. However, this has to be balanced against women having to wait longer to find out if their treatment was successful and they can return to routine recall.
In the era of ToC, this cohort includes a moderate number of treatments for CIN in a relatively stable population with the colposcopy system capturing smears on a national basis. 23 Taking all into consideration, we can be reassured that this cohort is representative of the United Kingdom. Our study results add to the current literature on the usefulness of ToC as a posttreatment curative success screening method.
There are a number of limitations in this study with the retrospective study design and lack of follow-up data because of patients' nonattendance being potential biases of this study. Furthermore, homogeneity of treatment and cytopathological accuracy may depend on quality control policies and experience.
CONCLUSIONS
The incorporation of Hr-HPV testing found a very small number of women with residual CIN detected within 12 months of treatment. Our results support the practice in England where women who are Hr-HPV positive and cytology negative after treatment of CIN with normal and adequate colposcopy are discharged to routine recall. If our findings are confirmed with national Scottish colposcopy data, this could support a change to our program guidance.
